GlobeNewswire

PCI Biotech: Extension of preclinical research collaboration agreement with a top-10 large pharma company

Share

Oslo (Norway), 22 July 2019 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that they are extending the preclinical research collaboration with an undisclosed top-10 pharma company. The pharma company is one of the global leaders in nucleic acid therapeutics and the collaboration was initiated in September 2015.

The aim of the extension is to further evaluate the synergistic effects of both parties' technology platforms in an in vivo setting and to determine whether PCI Biotech's fimaNAc technology has the potential to enhance the therapeutic effect of the partner's nucleic acid therapeutic compounds. The research collaboration is extended with 6 months until the end of 2019 and the companies have agreed to thereafter use the following 6 months (until end June 2020) to evaluate the potential for a further partnership.

Contact information:                 
Per Walday, CEO
pw@pcibiotech.no
Mobile: +47 917 93 429

About PCI Biotech         
PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead programme fimaChem consists of a pivotal study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.

For further information, please visit: www.pcibiotech.com                       

Forward-looking statements  
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Villkor för byten till ny realobligation SGB IL 311412.12.2019 09:30:00 CETPressemelding

Riksgälden introducerar en ny realobligation – SGB IL 3114 X% 1 Juni 30 – i februari 2020. Auktionsvillkor och kupong publiceras torsdagen den 30 januari kl. 16.20. I den första auktionen av SGB IL 3114 emitteras 500 miljoner kronor torsdagen den 6 februari 2020. Därefter erbjuds byten till den nya obligationen för att snabbt bygga upp volymen. Bytena görs dels kursriskneutralt1, dels likvidneutralt2 Bytesauktioner Fre 7 feb Kursriskneutralt Mån 10 feb Kursriskneutralt Tis 11 feb Likvidneutralt Riksgälden säljer obligation 3114 3114 3114 Riksgälden säljer belopp (mnkr) 2 000 1 000 2 000 Riksgälden köper obligation 3104 3112 3104 Riksgälden köper belopp (mnkr) 3 1 500 1 600 1 200 Tid för återköpsränta kl. 10.45 kl. 10.45 kl. 10.45 Tid för auktionens stängning kl. 11.00 kl. 11.00 kl. 11.00 Tid för auktionsresultat kl. 11.03 kl. 11.03 kl. 11.03 Den nya realobligationen annonserades i publikationen Statsupplåning – prognos och analys 2019:3 i oktober. Räntan på återköpslånet publiceras kl.

Terms for switches to inflation-linked bond SGB IL 311412.12.2019 09:30:00 CETPress release

The Swedish National Debt Office introduces a new inflation-linked bond – SGB IL 3114 X% 1 Jun 30 – in February 2020. The auction details and the coupon will be published on Thursday 30 January 2020 at 16.20. The Debt Office will issue SEK 500 million of SGB IL 3114 in a first auction on 6 February 2020. Thereafter switches to the new bond will be offered to quickly build up volume. The switches will be made price risk neutral1 as well as cash neutral2. Switch auctions Fri 7 Feb Risk neutral Mon 10 Feb Risk neutral Tue 11 Feb Cash neutral SNDO sells bond 3114 3114 3114 SNDO sells amount (SEK mn) 3 2 000 1 000 2 000 SNDO buys bond 3104 3112 3104 SNDO buys amount (SEK mn) 1 500 1 600 1 200 Time for yield on buy-back bond 10.45 10.45 10.45 Time for auction cut-off 11.00 11.00 11.00 Time for auction result 11.03 11.03 11.03 The new bond was announced in the publication Central Government Borrowing – Forecast and Analysis 2019:3 on 23 October 2019. The buy-back yield on the bond will be pub

Stephanie Werner appointed Chief Human Resources Officer and a member of the Nokia Group Leadership team as Hans-Jürgen Bill retires  12.12.2019 08:30:00 CETPress release

Nokia Corporation Stock Exchange Release December 12, 2019 at 9.30 (CET +1) Stephanie Werner appointed Chief Human Resources Officer and a member of the Nokia Group Leadership team as Hans-Jürgen Bill retires Espoo, Finland – Nokia today announced the appointment of Stephanie Werner, as Chief Human Resources Officer, effective January 1, 2020. Hans-Jürgen Bill, Nokia’s current Chief Human Resources Officer, will retire in May 2020. Stephanie Werner has been with Nokia since 1998 and has held various HR leadership positions in countries including China, Switzerland, Philippines, USA and Romania. She will be based in Finland. “I am pleased to be able to welcome Stephanie to take the lead on our people strategy during a critical time for Nokia,” said Rajeev Suri, President and Chief Executive Officer of Nokia. “She will play a key role in enabling our ongoing transformation and building a high-performance culture. I want to thank Hans-Jürgen for his many contributions to Nokia and wish hi

Aino Health AB (publ): Aino Health tecknar avtal med Centric Sverige gällande SaaS-lösningen HealthManager12.12.2019 08:25:00 CETPressemelding

Aino Health hat tecknat ett avtal, gällande SaaS-lösningen HealthManager, med Centric – ett It-företag som erbjuder konsulttjänster och IT outsourcing. Avtalet löper initialt över två år. I den första fasen kommer HealthManager att implementeras för ca 350 personer i Sverige, av de totalt 800 personer som är anställda i Norden. Centric har totalt 4500 anställda i Europa fördelat på 7 olika länder. Centric har letat efter en lösning som kan hjälpa dem att arbeta mer effektivt och strukturerat när det gäller de anställdas välmående och hälsa och som samtidigt kan stötta cheferna arbetssätt gällande detta. Målen med implementationen är högre närvaro och välmående hos de anställda. Projektets första fas är planerad att vara implementerad i december i år. HealthManager är en SaaS plattform som stöttar chefer med intern hälsorelaterade processer och frånvarohantering. kommunikation och engagemang. Tjänsten erbjuder verktyg för rapportering och analys för att följa nyckeltal kopplade till Cor

Aino Health AB (publ): Aino Health signs agreement with Centric Sweden regarding the SaaS solution HealthManager12.12.2019 08:25:00 CETPress release

Aino Health has signed an agreement, regarding the SaaS solution HealthManager, with Centric - an IT company offering consultants as well as IT outsourcing. The initial agreement is a two-year contract. In the first phase, HealthManager will be implemented for around 350 persons in Sweden out of the in total about 800 Centric employees in the Nordics. In Europe, Centric has more than 4500 employees in 7 countries. Centric has been looking for a solution that can help them to work in a more structural and efficient way regarding employee wellbeing and health, and at the same time support the managers’ way of working with this. The goals are to increase presence at work and the wellbeing of the personnel. The first phase of the project is projected to be live in December this year. HealthManager is a SaaS solution that supports managers with internal health-related processes and absence management. It also offers reporting and analytic tools to follow key metrics related to corporate hea

Nokia wins Deutsche Bahn tender to deliver and test the world’s first 5G-based network for automated rail operation12.12.2019 08:15:00 CETPress release

Press Release The solution is one of the world’s first standalone 5G networks used for automated rail operation. The project constitutes an essential milestone in the development of the 5G-based Future Railway Mobile Communication System (FRMCS) standard — the successor to the current GSM-R standard 12 December 2019 Espoo, Finland – Nokia has won a tender to test and deliver the world’s first standalone (SA) 5G system for automated rail operation in Hamburg, Germany. The project is part of Deutsche Bahn’s highly automated S-Bahn operation project. The proof-of-concept will test whether 5G technology is mature enough to be used as the connectivity layer for future, digitalized rail operations. The project constitutes an early and important step in the development of the Future Railway Mobile Communications System (FRMCS) standard, based on 5G, and sets the stage for the digital transformation of railway operations. Nokia is a leader in this market with extensive experience in providing